Virtus ETF Advisers LLC - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 84 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.5%.

Quarter-by-quarter ownership
Virtus ETF Advisers LLC ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$144,209
+50.1%
4,849
-9.1%
0.09%
+54.4%
Q2 2023$96,101
-3.7%
5,333
-14.2%
0.06%
+3.6%
Q1 2023$99,813
-36.6%
6,215
-27.7%
0.06%
-32.9%
Q4 2022$157,343
+29.0%
8,598
+38.1%
0.08%
+67.3%
Q3 2022$122,000
+6.1%
6,228
+0.8%
0.05%
+14.0%
Q2 2022$115,000
-17.3%
6,180
-2.6%
0.04%
-30.6%
Q1 2022$139,000
-27.2%
6,346
-5.6%
0.06%
-13.9%
Q4 2021$191,000
-19.1%
6,726
-40.1%
0.07%
-30.8%
Q3 2021$236,000
+5.8%
11,225
-5.0%
0.10%
+13.0%
Q2 2021$223,000
-33.2%
11,810
-46.0%
0.09%
-34.8%
Q1 2021$334,000
+10.2%
21,882
+1.8%
0.14%
+11.9%
Q4 2020$303,000
-0.3%
21,487
+10.9%
0.13%
-20.8%
Q3 2020$304,000
-21.2%
19,371
-12.1%
0.16%
-13.1%
Q2 2020$386,000
+113.3%
22,026
+177.6%
0.18%
-52.5%
Q1 2019$181,000
-33.2%
7,934
-12.2%
0.38%
+737.0%
Q4 2018$271,0009,0340.05%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q2 2021
NameSharesValueWeighting ↓
Saturn V Capital Management LP 623,819$11,336,5019.41%
Finepoint Capital LP 822,745$15,0564.87%
Bain Capital Life Sciences Investors, LLC 2,305,558$42,1924.72%
Opaleye Management Inc. 732,000$13,395,6004.66%
5AM Venture Management, LLC 862,286$15,779,8344.24%
SPHERA FUNDS MANAGEMENT LTD. 671,644$12,291,0852.64%
First Light Asset Management, LLC 1,329,313$24,326,4282.26%
BRAIDWELL LP 3,469,674$63,495,0342.13%
BVF INC/IL 2,736,613$50,080,0182.11%
Perceptive Advisors 4,039,276$73,918,7512.08%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders